Navigation Links
Argos Therapeutics' Arcelis™ Immunotherapy for the Treatment of Renal Cell Carcinoma (RCC) in Combination With Sunitinib Demonstrates Strong Immunologic Response That Correlates to Improved Clinical Outcomes
Date:6/1/2011

works as designed to address the underlying immune suppression observed in metastatic RCC patients, while also generating a highly specific and durable T-cell response that appears to improve clinical outcomes in terms of PFS, when combined with sunitinib," said Charles Nicolette, Ph.D., chief scientific officer and vice president of research and development of Argos. "This is the first prospective analysis of immunodynamics in RCC patients receiving sunitinib in combination with an immunotherapy, and we plan to confirm these positive results in a randomized setting in a Phase 3 clinical trial."

About the Arcelis™ Technology

Arcelis is Argos' proprietary technology for personalizing RNA-loaded dendritic cell immunotherapies for cancer, HIV and other infectious diseases. This platform is based on optimizing a patient's own (autologous) dendritic cells to trigger a tumor- or pathogen-specific immune response. To address the challenge of the unique genetic profile of each patient's disease and the genetic mutations of that disease, Argos loads the autologous dendritic cells with a sample of messenger RNA ("mRNA") isolated from the patient's disease. Through this process, dendritic cells can potentially prime immune responses to the entire antigenic repertoire, resulting in an immunotherapeutic that is customized to the patient's specific disease.

About Argos Therapeutics, Inc.

Argos is an immunotherapy company developing new treatments for cancer, infectious and autoimmune diseases and transplantation rejection. The Company has generated multiple platform technologies and a diverse pipeline of products based on its expertise in the biology of dendritic cells — the master switch that turns the immune system on or off. www.argostherapeutics.com

Contacts:

David Schull or Andreas
'/>"/>

SOURCE Argos Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Interleukin (IL)-12 Secretion Can Predict Potency of Argos Therapeutics Arcelis™ Dendritic Cell (DC) Immunotherapy and Can Be Used as Potency Marker in Phase 3 Clinical Trial
2. Argos Therapeutics to Present Potential of its Arcelis™ Immunotherapy as an Innovative, Effective Treatment for HIV at the APHA 138th Annual Meeting & Exposition
3. Argos Therapeutics to Present Overview of its Arcelis™ Dendritic Cell-based Immunotherapy, Participate in Panel Discussion at Inaugural Cancer Immunotherapy Conference
4. Argos Therapeutics to Present Recent Clinical Developments and Corporate Overview at 18th Annual BioPartnering Europe
5. Results From Argos Therapeutics Arcelis™ Immunotherapy Phase 2 Study for Treatment of Renal Cell Carcinoma (RCC) Accepted for Poster Presentation at Ninth International Kidney Cancer Symposium
6. Nektar Therapeutics President and CEO Howard W. Robin to Present at the Jefferies 2011 Global Healthcare Conference in New York
7. Reportlinker Adds Cancer Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2017
8. Reportlinker Adds Myelodysplastic Syndrome Therapeutics - Pipeline Assessment and Market Forecasts to 2017
9. Cell Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Rule
10. Amicus Therapeutics to Present at Jefferies 2011 Global Healthcare Conference on Tuesday, June 7, 2011
11. Reportlinker Adds Risk Evaluation and Mitigation Strategy (REMS) - Opioids, Erythropoesis-Stimulating Agents and Cancer Therapeutics are the Most Important Classes That Require REMS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... -- Revenue and earnings above the previous year ... In the past 2013/14 fiscal year (ended 30 ... EUR 4.287 billion (last year: EUR 4.190 billion) despite unfavorable ... 360 million. "Overall, 2013/14 was a successful fiscal year for ... and CEO of Carl Zeiss AG. "Thanks to our broad ...
(Date:12/17/2014)... With advancements in neurological and functional ... seeing new growth, according to Kalorama Information. Though ... the majority of market volume, newer 3T systems ... are creating opportunities for more sophisticated applications. The medical ... a rate of 4%, with world market revenues ...
(Date:12/17/2014)... , Dec. 17, 2014  ImmunoCellular Therapeutics, Ltd. ... Patent and Trademark Office (USPTO) has issued a ... dendritic cell-based immunotherapeutic vaccine targeting six tumor antigens ... of US Patent No. 8,871,211, which issued October ... by administering a dendritic cell composition comprising peptide ...
Breaking Medicine Technology:ZEISS Asserts its Position in Difficult Environment 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 3ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine 2
... studies of immunosuppression in kidney transplant ... Aug. 28 "Cylex, Inc., in association,with our Korean ... to,announce our support for a major, multi-center trial of ... medical institutions,in the Republic of Korea," stated Brad Stewart, ...
... - Results Further Support the Clinical Profile of ... Survival of Patients,With Hormone Refractory Prostate Cancer (HRPC), ... therapeutics company,today announced that the primary objective of ... The study showed that even single doses of,Alpharadin ...
Cached Medicine Technology:Cylex Announces Plan for Multi-Center Trial of ImmuKnow(R) Assay in South Korea 2Cylex Announces Plan for Multi-Center Trial of ImmuKnow(R) Assay in South Korea 3Algeta Reports Positive Headline Phase II Data on Pain Palliation With Alpharadin 2Algeta Reports Positive Headline Phase II Data on Pain Palliation With Alpharadin 3Algeta Reports Positive Headline Phase II Data on Pain Palliation With Alpharadin 4
(Date:12/19/2014)... December 19, 2014 The Hermitage ... club in Southern Vermont’s Deerfield Valley, announced today that ... by classic rock songs. , Three time Grammy ... a private concert followed by a trail naming ceremony. ... trail names include: “I’m Alright” the theme song for ...
(Date:12/19/2014)... A new study suggests a possible link between certain ... night sweats -- and higher rates of hip fractures ... menopause, affecting about 60 percent of women. The hormonal ... they then face a higher risk of weakened bones ... moderate or severe menopausal symptoms are more likely to ...
(Date:12/19/2014)... HealthDay Reporter THURSDAY, Dec. 18, 2014 (HealthDay ... high levels of air pollution late in pregnancy may have ... Researchers found that of nearly 1,800 U.S. women who ... most air pollution during pregnancy were twice as likely to ... the third trimester, specifically, showed the strongest correlation to autism ...
(Date:12/19/2014)... News) -- Traveling through the same U.S. airport gate, ... others within a four-hour time span, illustrating just how ... "The exposures in this report were not prolonged ... terminal, highlighting the fact that measles is highly contagious," ... disease specialist at the U.S. Centers for Disease Control ...
(Date:12/19/2014)... Reinberg HealthDay Reporter THURSDAY, ... on one leg for at least 20 seconds you may ... Difficulty standing on one leg may indicate that small strokes ... for more serious strokes is high, the investigators reported online ... showing instability while standing on one leg, as well as ...
Breaking Medicine News(10 mins):Health News:The Hermitage Club Officially Names Four Ski Trails after Iconic Rock Songs by Grammy Award Winner Kenny Loggins 2Health News:Severe Hot Flashes During Menopause May Raise Hip Fracture Risk Later: Study 2Health News:Smog Exposure During Pregnancy Linked to Autism Risk 2Health News:Smog Exposure During Pregnancy Linked to Autism Risk 3Health News:Arriving Now at Gate 42: Measles 2Health News:Arriving Now at Gate 42: Measles 3Health News:Can You Balance on One Leg? You May Have Lower Stroke Risk 2
... Jerry A. Boriskin of University of the Rockies Delivers ... when many military men and women are returning home ... member of the University of the Rockies and author ... to recognize and prevent post traumatic stress disorder (PTSD) ...
... Calif., Feb. 20 CUREXO Technology Corporation, pioneer ... robotic products for orthopaedic applications, which is focused ... it has submitted a premarket notification 510(k) application ... for market clearance in the U.S. for use ...
... Executive to Head Company,s Network of International Subsidiaries and ... (Nasdaq: CYNO ), a leading developer and ... systems, today announced the appointment of William T. Kelley ... will be responsible for the company,s direct subsidiaries in ...
... apt to die early, study finds, , , WEDNESDAY, Feb. 25 ... risk of premature death in adulthood as much as smoking ... , Dr. Martin Neovius of the Karolinska Institute and ... military conscription tests in which their body mass index (BMI) ...
... re-alignment of shared services, including Business Technology, ... Device Governance CommitteesROCKVILLE, Md. and PRINCETON, N.J., ... (OAPI) and Otsuka Pharmaceutical Development & Commercialization, ... part of the North American pharmaceutical organizations, ...
... CROSSFIT TRAINER ANDY PETRANEK TO TACKLE THE HOTTEST TREND ... medalist to the growing list of female athletes who ... is part of a burgeoning movement of professional female ... grueling, high-intensity workouts used to train the warrior actors ...
Cached Medicine News:Health News:Leading Cause of Stress to Military War Veterans Key Topic at 35th Advanced International Winter Symposium 2Health News:Leading Cause of Stress to Military War Veterans Key Topic at 35th Advanced International Winter Symposium 3Health News:CUREXO Technology Corporation Announces 510(k) Submission to FDA for Total Knee Arthroplasty Application 2Health News:Cynosure Appoints William T. Kelley as Senior Vice President of International Sales 2Health News:Cynosure Appoints William T. Kelley as Senior Vice President of International Sales 3Health News:Obesity Just as Risky for Teens as Heavy Smoking 2Health News:Otsuka America Pharmaceutical, Inc. and Otsuka Pharmaceutical Development & Commercialization, Inc. Announce Restructuring Changes Aimed at Growing Otsuka's Pharmaceutical Business Worldwide 2Health News:Otsuka America Pharmaceutical, Inc. and Otsuka Pharmaceutical Development & Commercialization, Inc. Announce Restructuring Changes Aimed at Growing Otsuka's Pharmaceutical Business Worldwide 3Health News:CrossFit: A Workout Fit for an Olympian 2
... Cochrane Reviews enable all those involved with ... with the very latest evidence in their ... becomes harder each year as the volume ... problem by delivering the best single source ...
Over 10,000 entries. This dictionary is both a home medical guide and as an aid for all those working in the medical and allied professions. The entries are laid out and jargon-free....
... for PDA is a combination of the Medical ... Dictionary pocket for PDA. The first part of ... overview of the Spanish language, i.e. pronunciation, common ... of anatomy and medical terminology. The second part ...
Taber's Cyclopedic Medical Dictionary is published by F.A. Davis. Contains approximately 56,000 terms....
Medicine Products: